tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

ORKA Stock Latest News

Oruka Therapeutics: Promising Clinical Developments and Strong Financial Health Justify Buy Rating
RatingsOruka Therapeutics: Promising Clinical Developments and Strong Financial Health Justify Buy Rating
2d ago
ORKA
Promising Prospects for Oruka Therapeutics: Buy Rating Backed by Strong Growth and Financial Stability
PremiumRatings
Promising Prospects for Oruka Therapeutics: Buy Rating Backed by Strong Growth and Financial Stability
6d ago
ORKA
Oruka Therapeutics Reports Q2 2025 Financial Results
PremiumCompany Announcements
Oruka Therapeutics Reports Q2 2025 Financial Results
6d ago
ORKA
Oruka Therapeutics: Promising Clinical Developments and Strong Financial Position Justify Buy Rating
PremiumRatings
Oruka Therapeutics: Promising Clinical Developments and Strong Financial Position Justify Buy Rating
6d ago
ORKA
Oruka Therapeutics reports Q2 EPS (46c), consensus (43c)
PremiumThe Fly
Oruka Therapeutics reports Q2 EPS (46c), consensus (43c)
6d ago
ORKA
Oruka Therapeutics: Promising Pipeline and Strategic Advancements Drive Buy Rating
PremiumRatingsOruka Therapeutics: Promising Pipeline and Strategic Advancements Drive Buy Rating
26d ago
ORKA
Strong Buy Recommendation for Oruka Therapeutics: Promising Pipeline and Attractive Valuation
Premium
Ratings
Strong Buy Recommendation for Oruka Therapeutics: Promising Pipeline and Attractive Valuation
26d ago
ORKA
Positive Outlook for Oruka Therapeutics: ORKA-001’s Promising Phase 2a Trial and Potential Market Differentiation
Premium
Ratings
Positive Outlook for Oruka Therapeutics: ORKA-001’s Promising Phase 2a Trial and Potential Market Differentiation
27d ago
ORKA
Oruka Therapeutics announces IND clearance for EVERLAST-A Phase 2a trial
PremiumThe Fly
Oruka Therapeutics announces IND clearance for EVERLAST-A Phase 2a trial
28d ago
ORKA
Oruka Therapeutics: A Promising Contender in the $30 Billion Psoriasis Market with Innovative Treatments ORKA-001 and ORKA-002
PremiumRatings
Oruka Therapeutics: A Promising Contender in the $30 Billion Psoriasis Market with Innovative Treatments ORKA-001 and ORKA-002
1M ago
ORKA
Oruka Therapeutics Appoints New Chief Operating Officer
PremiumCompany Announcements
Oruka Therapeutics Appoints New Chief Operating Officer
2M ago
8K
ORKA
Oruka Therapeutics Holds Annual Stockholders Meeting
PremiumCompany Announcements
Oruka Therapeutics Holds Annual Stockholders Meeting
3M ago
8K
ORKA
Oruka Therapeutics: Promising Pipeline and Strategic Developments Justify Buy Rating
PremiumRatingsOruka Therapeutics: Promising Pipeline and Strategic Developments Justify Buy Rating
3M ago
ORKA
Oruka Therapeutics initiated with a Buy at BTIG
Premium
The Fly
Oruka Therapeutics initiated with a Buy at BTIG
3M ago
ORKA
Buy Rating for Oruka Therapeutics: Promising Pipeline and Strong Financial Position
Premium
Ratings
Buy Rating for Oruka Therapeutics: Promising Pipeline and Strong Financial Position
3M ago
ORKA
Oruka Therapeutics: Strong Financial Position and Promising Clinical Developments Support Buy Rating
PremiumRatings
Oruka Therapeutics: Strong Financial Position and Promising Clinical Developments Support Buy Rating
3M ago
ORKA
Oruka Therapeutics reports Q1 EPS (40c), consensus (47c)
PremiumThe Fly
Oruka Therapeutics reports Q1 EPS (40c), consensus (47c)
3M ago
ORKA
Oruka Therapeutics’ ORKA-001: Promising Developments and Buy Rating Justification
PremiumRatings
Oruka Therapeutics’ ORKA-001: Promising Developments and Buy Rating Justification
4M ago
ORKA
Oruka Therapeutics Reports Strong 2024 Financial Results
PremiumCompany Announcements
Oruka Therapeutics Reports Strong 2024 Financial Results
5M ago
ORKA
Oruka Therapeutics at Risk: Navigating Licensing Challenges and Partner Reliance
PremiumCompany AnnouncementsOruka Therapeutics at Risk: Navigating Licensing Challenges and Partner Reliance
5M ago
ORKA
Buy Rating for Oruka Therapeutics: Promising Drug Pipeline and Strategic Trial Design
Premium
Ratings
Buy Rating for Oruka Therapeutics: Promising Drug Pipeline and Strategic Trial Design
5M ago
ORKA
Oruka Therapeutics announces preclinical data for ORKA-002
Premium
The Fly
Oruka Therapeutics announces preclinical data for ORKA-002
5M ago
ORKA

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >